Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73*
暂无分享,去创建一个
A. Levine | L. Castagnoli | G. Cesareni | M. Oren | G. Blandino | S. Strano | Y. Shaul | A. Sacchi | M. Rossi | B. Cristofanelli | E. Munarriz | Barbara Cristofanelli
[1] A. Jochemsen,et al. Physical Interaction between Wilms Tumor 1 and p73 Proteins Modulates Their Functions* , 2000, The Journal of Biological Chemistry.
[2] A. Yang,et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours , 2000, Nature.
[3] Hua Lu,et al. The N-Terminal Domain of p73 Interacts with the CH1 Domain of p300/CREB Binding Protein and Mediates Transcriptional Activation and Apoptosis , 2000, Molecular and Cellular Biology.
[4] M. Oren. Regulation of the p53 Tumor Suppressor Protein* , 1999, The Journal of Biological Chemistry.
[5] W. Kaelin. The p53 gene family , 1999, Oncogene.
[6] K. Vousden,et al. Mdm2 binds p73α without targeting degradation , 1999, Oncogene.
[7] T. Davison,et al. p73 and p63 Are Homotetramers Capable of Weak Heterotypic Interactions with Each Other but Not with p53* , 1999, The Journal of Biological Chemistry.
[8] Jijie Gu,et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage , 1999, Nature.
[9] Reuven Agami,et al. Interaction of c-Abl and p73α and their collaboration to induce apoptosis , 1999, Nature.
[10] Antonio Costanzo,et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.
[11] W. Kaelin,et al. MDM2 Suppresses p73 Function without Promoting p73 Degradation , 1999, Molecular and Cellular Biology.
[12] G Melino,et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ , 1999, Cell Death and Differentiation.
[13] Christopher P. Crum,et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.
[14] H. Vogel,et al. p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.
[15] W. Kaelin. The emerging p53 gene family. , 1999, Journal of the National Cancer Institute.
[16] D. Tindall,et al. Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.
[17] C. Prives,et al. p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.
[18] A. Levine,et al. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.
[19] C. Prives,et al. The p53 pathway , 1999, The Journal of pathology.
[20] F. Haluska,et al. Mutational and expression analysis of the p73 gene in melanoma cell lines. , 1999, Cancer research.
[21] J. Pipas,et al. Adenovirus E4orf6 oncoprotein modulates the function of the p53-related protein, p73. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Roth,et al. The large T antigen of simian virus 40 binds and inactivates p53 but not p73. , 1998, The Journal of general virology.
[23] W. Stolz,et al. Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas , 1998, Melanoma research.
[24] N. Nomura,et al. p73, a geme related to p53, is not mutated in esophageal carcinomas , 1998, International journal of cancer.
[25] G. Melino,et al. Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity , 1998, Journal of Experimental Medicine.
[26] W. Kaelin,et al. Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73 , 1998, Molecular and Cellular Biology.
[27] Moshe Oren,et al. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs , 1998, Oncogene.
[28] A. Yang,et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.
[29] M. Herlyn,et al. p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. , 1998, International journal of oncology.
[30] J. Cleveland,et al. Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.
[31] V. Rotter,et al. Mutant p53 protein expression interferes with p53-independent apoptotic pathways , 1998, Oncogene.
[32] D. Tindall,et al. Activation of p73 silent allele in lung cancer. , 1998, Cancer research.
[33] A. Nakagawara,et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. , 1998, Cancer Research.
[34] K. Aldape,et al. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] S. Nomoto,et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. , 1998, Cancer research.
[36] W. Kaelin,et al. p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.
[37] M. Oren. Lonely No More: p53 Finds Its Kin in a Tumor Suppressor Haven , 1997, Cell.
[38] A. Yang,et al. Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.
[39] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[40] M. Oren,et al. p53; from inductive signal to cellular effect. , 1997, Current opinion in genetics & development.
[41] G. Thomas,et al. P53 gene alterations in human tumors: perspectives for cancer control. , 1997, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[42] N. Nomura,et al. RN-tre specifically binds to the SH3 domain of eps8 with high affinity and confers growth advantage to NIH3T3 upon carboxy-terminal truncation. , 1996, Oncogene.
[43] N. Nomura,et al. RN-tre identifies a family of tre-related proteins displaying a novel potential protein binding domain. , 1996, Oncogene.
[44] R. Evans,et al. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[45] P. Pelicci,et al. A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[46] E. Shaulian,et al. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. , 1995, Genes & development.
[47] A. Levine,et al. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.
[48] A. Levine,et al. Gain of function mutations in p53 , 1993, Nature Genetics.
[49] E. Shaulian,et al. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.
[50] S. Steinberg,et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. , 1992, Oncogene.
[51] O. Halevy,et al. p53 Mutations: Gains or losses? , 1991, Journal of cellular biochemistry.
[52] A. Levine,et al. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.
[53] D. Lane,et al. T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.